ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Background: Despite their potential, Glucagon-like peptide ... 1 RA. Patients were assessed at follow-up periods of 1 month and 1 year. Propensity score-matched analysis (PSM) (1:1) was performed with ...

originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous report on directly targeting tumor cells via glucose transporter 1 (GLUT1), they tried to uncover ...

1 Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 ... The discovery that global muscle hypertrophy has anti-obesity and anti-diabetic effects prompts critical ...